Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Axio BioPharma Partners with eMBR Genomics to Manufacture and Distribute Proprietary MKLP1 Pro™ Antibodies

manufacturing and flexible production capabilities to support a wide range of clients, including researchers, pharmaceutical companies, and diagnostic developers, in achieving streamlined workflows and consistent, high-quality outcomes. About eMBR...

"Fresenius Kabi expands its U.S. pharma portfolio with the launch of Epinephrine Injection, USP

Leadership Team, Fresenius Kabi AG. Fresenius Kabi has invested nearly $1 billion to expand and update its U.S. pharmaceutical production and distribution facilities. Fresenius Kabi is committed to domestic production. More than 70 percent of the...

Isotopia collaborates with LIVEKIDNEY.BIO, marking a breakthrough in lupus treatment advancements

and safer treatment options than those currently available. About Isotopia: Isotopia is a global leader in radiopharmaceutical solutions, specializing in high-quality aseptic and lyophilized drug products for clinical trials and commercial use....

MM+M honors Petauri's Nicole Lodowski as a 2025 40 Under 40 awardee

Petauri, a leading purpose-built pharmaceutical services platform, announced that Nicole Lodowski, Managing Director of Petauri Evidence, has been recognized as one of MM+M's esteemed 40 Under 40 honorees for 2025. Amanda Peterson, Vice President...

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

regulatory authorities to expedite PLT012's development and availability. Pilatus Biosciences, a preclinical-stage biopharmaceutical company spun out from the Ludwig Institute for Cancer Research (Lausanne), is leading the development of...

Biolexis Therapeutics reports positive outcomes for BLX-7006 in an expanded Diet-Induced Obesity (DIO) model study

lives of those affected by chronic metabolic diseases." About Biolexis Therapeutics: Biolexis Therapeutics is a biopharmaceutical company focused on discovering and developing innovative metabolic drugs to address chronic diseases such as obesity,...

SciTech Development reveals promising Phase 1A trial results for T-cell non-Hodgkin lymphoma therapy

SciTech Development, a clinical-stage pharmaceutical company focused on advancements in cancer treatment, is excited to share promising updates from its clinical trial of ST-001 nanoFenretinide (ST-001). Preliminary Trial Findings: Preliminary...

Dr. Jonathan Sadeh, ex-SVP of Immunology R&D at Bristol-Myers Squibb, joins Scinai Immunotherapeutics' Scientific Advisory Board

Scinai Immunotherapeutics Ltd. a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced that Dr. Jonathan Sadeh has...

NS Pharma announces a leadership change, appointing new commercial head to drive strategic growth and innovation

muscle-wasting neurological disorder. Prior to joining NS Pharma, Foy served in leadership roles for 17 years in the pharmaceutical industry, with more than 24 years of experience both in sales and in cross-functional positions supporting a diverse...

Pharmaceutics and Drug Delivery Systems 2024

This conference features state of the art presentations and discussions on current practice and new developments in pharmaceutical sciences and focus on the theme “Exploration of the frontiers in the field of Pharmaceutical Sciences”.

Hanmi Pharmaceutical and Beijing Hanmi advance clinical trials for BH3120, their co-developed next-generation cancer immunotherapy

The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, was recently presented at a major global academic conference, drawing significant...

Preclinical study shows NUZ-001 reduces TDP-43 aggregation in ALS

that stem cell technology will help bring better therapies to patients faster. The company's goal is to enable biopharmaceutical companies in drug discovery to accelerate their development processes through the integration of human iPSC...

GenScript's ProBio subsidiary plays a key role in cutting-edge cancer therapies

the most trustworthy biotech company in the world. ABOUT PROBIO: ProBio is a global leader in enabling biotech and pharmaceutical companies to advance the development and manufacturing of next-generation therapies. As a fully integrated end-to-end...

Axonal.AI launches an industry-first platform to accelerate life sciences time to market

rapid commercialization is more critical than ever, Axonal.AI's cutting-edge technology promises to transform how pharmaceutical companies bring products to market. Tailored specifically for the pharmaceutical sector, the platform allows...

Orsini begins distribution of CASGEVY® (exagamglogene autotemcel), a gene-editing therapy

Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene autotemcel). CASGEVY is a CRISPR/Cas9 gene-edited cell therapy indicated for the treatment of patients aged 12 years and older...

ResQ Pharma receives PDUFA date for LipidRescue™, potentially the first FDA-approved treatment for Local Anesthetic Systemic Toxicity (LAST)

ResQ Pharma, Inc., a Chicago-based pharmaceutical company developing and commercializing innovative drug therapies, today announced that it has received a PDUFA (Prescription Drug User Fee Act) date of June 2, 2025, for its LipidRescue Kit. If...

SystImmune secures FDA clearance for BL-M17D1 IND in advanced solid tumors

space and bring potentially best-in-class products to patients." About SystImmune: SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug...

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

with FTD have a mean survival of nine years. About Transposon: Transposon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a platform of novel therapies for the treatment of neurodegenerative and aging-related diseases,...

HanAll Biopharma releases Q3 2024 financial results and shares business updates

HanAll Biopharma Co., Ltd. a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the third quarter of 2024 and provided business updates. HanAll ended the third...

GoodRx debuts a new e-commerce platform, starting with Opill®

into the over-the-counter (OTC) market, but it offers valuable partnership opportunities for consumer health and pharmaceutical brands looking to leverage GoodRx’s extensive reach and scale. The introduction of this new e-commerce service is part...